MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Acrivon Therapeutics, Inc. (NASDAQ: ACRV)
Organization & Developments: Acrivon
Parents
Acrivon Therapeutics, Inc. (NASDAQ: ACRV)
Children
*Powered by AP3 platform they match drug mechanisms to the biologic drivers of cancer in patients, uncovering drug sensitivity not achievable through genomics.
*The firm is a clinical stage biopharma developing treatments for ovarian, endometrial and bladder cancers
2022: Acrivon Therapeutics Begins U.S. IPO Rollout_seekingalpha.com
2024: Acrivon Therapeutics Launches Phase 1 Cancer Trial, Advances Oncology Pipeline
2024: Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
2024: Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
2024: Acrivon's Cancer Drug Shows 62.5% Response Rate; Reports $202.8M Cash Position
Jumps
Finance & Acquisitions: Acrivon
Key People: Acrivon